Related Experiment Video
Updated: May 27, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Mycophenolate mofetil for the induction and maintenance treatment of lupus nephritis
Tania C González-Rivera1, Joseph McCune
1University of Michigan, 3918 Taubman Center, Ann Arbor, MI 48109, USA. taniagon@med.umich.edu
Abstract:
Mycophenolate mofetil (MMF) inhibits purine synthesis by inhibiting inosine-5'-monophosphate dehydrogenase. Since 1995, it has been approved in the USA for the prevention of allograft rejection in solid organ transplant patients. In the last two decades, it has been frequently used as an immunosuppressive therapy for numerous autoimmune conditions including lupus nephritis. Management of lupus nephritis has been advanced by well-designed randomized clinical trials establishing MMF as a viable alternative to established therapies such as pulse intravenous cyclophosphamide in selected patients. This article outlines the pharmacologic properties of MMF and summarizes recent randomized clinical trials in lupus nephritis.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Myocarditis IV: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

